
-
Travere Therapeutics NasdaqGM:TVTX Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Location: 3611 Valley Centre Drive, San Diego, CA, 92130, United States | Website: https://www.travere.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
1.444B
Cash
322.2M
Avg Qtr Burn
-40.17M
Short % of Float
13.21%
Insider Ownership
0.75%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
FILSPARI (Sparsentan) Details Kidney disease, IgA nephropathy | Approved Quarterly sales | |
THIOLA® EC (tiopronin) Details Kidney disease, Cystinosis | Approved Quarterly sales | |
FILSPARI (Sparsentan) Details IgA nephropathy, Kidney disease | Approved Quarterly sales | |
FILSPARI (Sparsentan) Details IgA nephropathy, Kidney disease | PDUFA Approval decision | |
FILSPARI (Sparsentan) Details Kidney disease, Focal segmental glomerulosclerosis | sNDA Acceptance for review | |
CDCA (Chenodal/ chenodeoxycholic acid) Details Cerebrotendinous xanthomatosis | Phase 3 Data readout | |
Pegtibatinase (TVT-058) Details Homocystinuria | Phase 3 Initiation | |
Sparsentan Details Kidney disease, Glomerular diseases | Phase 2 Update |